NYSE · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC · SMALL CAP
Cryo-cell International, Inc. CCEL
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$31.6M
▼ 1.3% vs FY2024
EPS · FY25
$-0.30
Dividend / sh · FY25
—
Payout · FY25
-133%
ROE · FY25
—
Net margin · FY25
-7.7%
Dividend coverage
0.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 31.6M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 8 cents on every revenue dollar this year.
Per share
USD -0.30
Diluted EPS, FY2025
EPS
Dividend
Earnings covered only a fraction of the dividend — the rest came from cash or borrowing.
Profitability
—
Return on equity, FY2025
ROE
Operating margin1.5%
Net margin-7.7%
Return on assets-3.8%
Returned to shareholders
USD 3.4M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 3.2M
Net buybacksUSD 146,401.00
Share of profit-139.0%
Consecutive raises—
USD 3.2M in dividends and USD 146,401.00 in buybacks went back to shareholders in a year without profit.
Growth
+0.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+1.3%
+0.3%
+4.1%
+3.9%
Returned to shareholders
−27.7%
+0.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+6.8%
Change, 10 years−10.6%
The share count grew 7% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 61.7M
total assets, end of FY2025
Total assetsUSD 61.7M
EquityUSD -18.6M
CashUSD 319,031.00
Gross debtUSD 8.4M
Net debtUSD 8.0M
Current ratio0.59×
Net debt stands at -43% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
EBITDA $B
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
·
Income tax $B
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
EPS, diluted $
−0.30
0.05
−1.14
0.33
0.25
0.45
0.27
−0.11
0.30
−0.16
0.83
0.05
0.00
−0.56
−0.18
0.29
Dividend / sh $
·
0.25
·
0.90
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
−133
503
−0
277
0
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
208.4
274.3
·
·
·
·
·
·
·
·
·
·
·
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed